Inform Diagnostics (MLS), the leading pathology services provider that
collaborates to make patients and practices better, is pleased to announce
the results of a screening program implemented in 2010 which tests pre-cancerous
polyps for DNA mismatch repair (MMR) abnormalities. Throughout this program,
MLS leveraged its unique expertise and systematic approach to pathologic
evaluations to ensure the highest quality, efficacious, and cost-effective
program to improve the health of our patients and their families.
Lynch syndrome (LS), with the major cause of Hereditary Non-Polyposis Colorectal
Cancer (HNPCC) is the most common hereditary cause of early-onset colorectal
and endometrial cancers. This autosomal dominant disorder also leads to
increased risk of cancers of the stomach, small bowel, biliary tract,
kidneys, ureters, ovaries, brain, and pancreas. LS accounts for approximately
3.5% of colorectal cancers (CRC) (1 out of every 35 CRC patients), and,
after surgical resection, these patients have a >30% risk for other
cancers, both at the time of surgery and subsequently. Identification
of LS patients and affected family members allows for increased cancer
surveillance and hopefully reduced morbidity and mortality related to
A LS diagnosis previously relied on clinical criteria and family history;
neither of which is highly sensitive or specific, resulting in a large
number of LS cases remaining undiagnosed.
James M. Gulizia, M.D., Ph.D. and Director of MLS’ GI Quality Assurance
Program, explains, “This program was initiated to not only test
all newly diagnosed colorectal adenocarcinomas, but also high grade precancerous
polyps and precancerous polyps in individuals less than 40 years of age.
While other institutions have also adopted MMR screening programs for
CRC, Inform Diagnostics has taken a leadership role in screening these
precancerous polyps which can help identify at-risk patients before cancer
develops.” In fact, the program at MLS has found that the detection
rate among those with these pre-cancerous lesions is almost as high as
for those who already have cancer.
The MLS MMR screening program, including MLS’s evaluation of certain
patients with precancerous polyps, identified 360 people (as of July 2013)
with probable LS who would otherwise be unaware.
To read about research being done at MLS, please visit www.MiracaLifeSciences.com/Publications.
About Inform Diagnostics
Serving more than 5,500 patients each day, Inform Diagnostics is a leader
in providing an academic-caliber pathology laboratory with diagnostic
services in the fields of dermatology, gastroenterology, hematology and
urology. Building upon our experience with health IT, we also offer accessible
technology solutions to assist healthcare professionals as they work towards
accordance with Meaningful Use initiatives.
Inform Diagnostics, a wholly-owned subsidiary of Japan-based Inform Diagnostics Holdings
Inc., employs a talented team of leading pathologists, histologists, lab
technicians, technology consultants, and other medical professionals —
all driven to help provide the highest and most up-to-date levels of diagnostic
quality, enhanced workflow and practice solutions possible. It is part
of our commitment: not only to scientific excellence, but to patients